Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Inhibiting PI3Kγ in acute myeloid leukemia

Nature Cancer volume 5, pages 958–959 (2024)Cite this article

Subjects

The mainly hematologic expression profile of phosphatidylinositol-3-kinase-γ (PI3Kγ) makes it an attractive therapeutic target. Recent work from three independent groups shows that inhibiting PI3Kγ impairs the metabolism and growth of acute myeloid leukemia cells — a finding that justifies further mechanistic and clinical exploration.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cell-intrinsic role of PI3Kγ in AML.

References

  1. Okkenhaug, K., Graupera, M. & Vanhaesebroeck, B. Cancer Discov. 6, 1090–1105 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Goncalves, M. D., Hopkins, B. D. & Cantley, L. C. N. Engl. J. Med. 379, 2052–2062 (2018).

  3. Kaneda, M. M. et al. Nature 539, 437–442 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. De Henau, O. et al. Nature 539, 443–447 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hong, D. S. et al. Clin. Cancer Res. 29, 2210–2219 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kelly, L. M. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00782-5 (2024).

  7. Luo, Q. et al. Nature 630, 198–205 (2024).

    Article  CAS  PubMed  Google Scholar 

  8. Gu, H. et al. Blood 143, 1965–1979 (2024).

    Article  CAS  PubMed  Google Scholar 

  9. Tsherniak, A. et al. Cell 170, 564–576.e16 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Winter, G. E. et al. Science 348, 1376–1381 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. André, F. et al. N. Engl. J. Med. 380, 1929–1940 (2019).

    Article  PubMed  Google Scholar 

  12. Skånland, S. S. & Brown, J. R. Haematologica 108, 9–21 (2023).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Aaron J. Stonestrom & Ross L. Levine

  2. Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Aaron J. Stonestrom

Authors
  1. Aaron J. Stonestrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ross L. Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ross L. Levine.

Ethics declarations

Competing interests

A.J.S.’s spouse is an employee of Astra Zeneca. R.L.L. is on the supervisory board of Qiagen; is a scientific advisor to Mission Bio, Zentalis, Ajax, Auron, Prelude, and C4 Therapeutics, for which he receives equity; receives research support from Calico, Zentalis and Ajax; consults for Incyte and Janssen; and receives honoraria from Astra Zeneca for invited lectures.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stonestrom, A.J., Levine, R.L. Inhibiting PI3Kγ in acute myeloid leukemia. Nat Cancer 5, 958–959 (2024). https://doi.org/10.1038/s43018-024-00791-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-024-00791-4

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer